AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ImageneBio, Inc. Director's Dealing 2024

Feb 2, 2024

34275_dirs_2024-02-02_6681738c-05b7-41e4-86b3-d200ef6b6a2c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2024-02-01

Reporting Person: Marango Jotin (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-01	Stock Option (Right to Buy)	$1.36	A	181000	Acquired	2034-02-01	Common Stock (181000)	Direct

Footnotes

F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter.